[18F]F-FDG PET/CT能否用于评估结直肠癌患者腹膜癌病的术前范围
回顾性纳入2010年1月1日至2013年12月31日期间在CRS-HIPEC术前接受PET/CT扫描的35例患者,两位核医学医师独立评估腹膜内异常,采用简化PCI比较rPCI与sPCI。PET/CT低估了手术所见腹膜癌病范围,对腺癌及黏液腺癌或印戒细胞癌均相关性差,不推荐用于腹膜内肿瘤评分。
要点
- PET/CT低估结直肠癌腹膜癌病的范围,不推荐用于腹膜内肿瘤评分。
- 与手术数据相比,PET/CT评估腹膜癌病范围的相关性差。
- 简化PCI的rPCI中位数低于sPCI中位数,差异有统计学意义。
核心结论
- PET/CT低估了黏液性和非黏液性结直肠癌手术时的腹膜癌病范围,不推荐用于腹膜内肿瘤评分。
研究设计与样本
- 回顾性纳入2010年1月1日至2013年12月31日期间在CRS-HIPEC术前接受PET/CT扫描的患者35例,由两位核医学医师独立阅片评估腹膜内异常,以手术数据为参考标准,采用简化PCI比较rPCI与sPCI。
关键影像表现/征象
- PET/CT低估了手术所见的腹膜癌病范围,对腺癌及黏液腺癌或印戒细胞癌均相关性差。
诊断标准与关键数值
- 观察者1的rPCI中位数5.0(3.0-7.0)低于sPCI中位数9.5(5.0-11.8),P=0.02。
- 观察者2的rPCI中位数4.0(3.0-6.0)低于sPCI中位数9.5(5.0-11.8),P=0.01。
- 腺癌中PET/CT与手术数据评估腹膜癌病范围的相关性:观察者1 rho -0.17(P=0.51),观察者2 rho 0.13(P=0.61)。
- 黏液腺癌或印戒细胞癌中PET/CT与手术数据评估腹膜癌病范围的相关性:观察者1 rho 0.44(P=0.08),观察者2 rho 0.38(P=0.14)。
临床应用与阅片要点
- PET/CT不推荐用于腹膜内肿瘤评分。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate whether PET/CT could be used to assess the extent of colorectal peritoneal metastases.
METHODS: All patients who underwent a PET/CT scan before a CRS-HIPEC procedure between January 1, 2010 and December 31, 2013 were retrospectively included (n = 35). Two nuclear medicine physicians (observer 1 and observer 2) separately reviewed the scans on intraperitoneal abnormalities. A simplified PCI was used to compare the extent of rPCI versus sPCI.
RESULTS: Included patients had a median age of 60.6 years. Histology of primary tumors were 51.5% adenocarcinomas, 37.1% mucinous adenocarcinoma, and 11.4% SRCC. Median sPCI was 9.5 (5.0-11.8) and median rPCI was 5.0 (3.0-7.0) for observer 1 and 4.0 (3.0-6.0) for observer 2 (p = 0.02 and p = 0.01, respectively). When compared to the surgical data, PET/CT showed a poor correlation for assessing the extent of PC for both adenocarcinoma (observer 1 rho - 0.17, p = 0.51 and observer 2 rho 0.13, p = 0.61) as well as mucinous carcinoma or SRCC (observer 1 rho 0.44, p = 0.08 and observer 2 rho 0.38, p = 0.14).
CONCLUSION: PET/CT underestimates the extent of PC during surgery in both mucinous and non-mucinous CRC and is not recommended for intraperitoneal tumor scoring.
引用
- Elekonawo FMK, Starremans B, Laurens ST, et al. Can [18F]F-FDG PET/CT be used to assess the pre-operative extent of peritoneal carcinomatosis in patients with colorectal cancer? Abdom Radiol (NY). 2020. PMID: 31642963. doi:10.1007/s00261-019-02268-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。